0001562180-24-005791.txt : 20240717 0001562180-24-005791.hdr.sgml : 20240717 20240717195652 ACCESSION NUMBER: 0001562180-24-005791 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240715 FILED AS OF DATE: 20240717 DATE AS OF CHANGE: 20240717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quigley Jill M. CENTRAL INDEX KEY: 0001799780 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39926 FILM NUMBER: 241123475 MAIL ADDRESS: STREET 1: TWO COMMERCE SQUARE, 2001 MARKET STREET STREET 2: 28TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Terns Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001831363 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100 CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-525-5535 EXT.101 MAIL ADDRESS: STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-07-15 false 0001831363 Terns Pharmaceuticals, Inc. TERN 0001799780 Quigley Jill M. C/O TERNS PHARMACEUTICALS, INC. 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 true false false false true Common Stock 2024-07-15 4 M false 14365.00 1.82 A 44365.00 D Common Stock 2024-07-15 4 S false 14365.00 10.0007 D 30000.00 D Common Stock 2024-07-16 4 M false 400.00 1.82 A 30400.00 D Common Stock 2024-07-16 4 S false 400.00 10.00 D 30000.00 D Stock Option (Right to Buy) 1.82 2024-07-15 4 M false 14365.00 0.00 D 2023-06-12 2032-06-15 Common Stock 14365.00 17635.00 D Stock Option (Right to Buy) 1.82 2024-07-16 4 M false 400.00 0.00 D 2023-06-12 2032-06-15 Common Stock 400.00 17235.00 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024. This sale price represents the weighted average sale price of the shares sold ranging from $10.00 to $10.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The option vested in full immediately prior to the Annual Meeting following the date of grant. /s/ Bryan Yoon as Attorney-in-Fact for Jill M. Quigley 2024-07-17